Pharmaceutical

GSK concludes Aiolos Bio acquisition for $1.4bn

GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.

Feb 16, 2024 - 18:00
GSK concludes Aiolos Bio acquisition for $1.4bn
GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.
Read the original article

Tags:

Previous Article

Xyphos and Kelonia link for immuno-oncology drug development

Next Article

Psychedelic treatments for mental health: Is there substance behind the hype?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

With cancer expected to surge 77% worldwide by 2050, an oncologist weighs in on global disparities

With cancer expected to surge 77% worldwide by 2050, an...

Feb 5, 2024

STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee

STAT+: Novartis claims Takeda is stonewalling efforts t...

Oct 26, 2023

Seventh patient ‘cured’ of HIV among highlights at AIDS 2024

Seventh patient ‘cured’ of HIV among highlights at AIDS...

Jul 20, 2024